The global psychedelic drugs market size was estimated at USD 5.82 billion in 2025 and is predicted to increase from USD 6.68 billion in 2026 to approximately USD 23.14 billion by 2035, expanding at a CAGR of 14.8% from 2026 to 2035. A rise in the unmet mental health needs globally is increasing the demand for psychedelic drugs. Increasing regulator agencies' support, R&D activities, healthcare investments, and new product launches are enhancing the market growth.
The psychedelic drugs market is driven by the escalating global mental health crisis. The psychedelic drugs encompass the drugs that are used to alter thought, mood, and perception. These drugs are used for the treatment of depression, PTSD, anxiety disorders, and addictions.
AI is used in drug discovery and development as well as to help optimize clinical trials. It is also used in the development of personalized treatments, drug safety monitoring, and supports psychedelic experience simulation. AI also offers chatbots to support mental health therapies, as well as support drug safety monitoring and data analysis.
Expanding Clinical Trials
The growing innovation of psychedelic drugs is promoting clinical trials, where the fast-track approvals are also increasing their advancements. Expanding clinical pipeline, including psychedelic drugs for depression, PTSD, anxiety, and substance abuse, is also driving the clinical trials.
Focus on Addiction Treatment
As addiction is one of the major health challenges, there is a rise in the development of addiction treatments. This is driving the studies for opioid addiction, substance abuse disorder, and alcohol dependence.
Rise of Safer Next-Generation Psychedelic Drugs
To enhance public acceptance rates, the companies are developing psychedelic drugs with enhanced safety, effectiveness, and offering reduced side effects. This is driving their development of non-hallucinogenic or short-acting psychedelic drugs.
| Table | Scope |
| Market Size in 2026 | USD 6.68 Billion |
| Projected Market Size in 2035 | USD 23.14 Billion |
| CAGR (2026 - 2035) | 14.8% |
| Leading Region | North America by 46% |
| Key Applications | Depression, PTSD, Anxiety Disorders, Substance Use Disorders, Bipolar Disorder, Neurological Disorders |
| Primary End Users | Hospitals, Psychiatric Clinics, Specialty Psychedelic Therapy Centers, Rehabilitation Centers, Research Institutes |
| Key Growth Drivers | Rising mental health burden, favorable regulatory developments, increasing clinical trials, growing healthcare investments, AI-assisted drug discovery |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Drug Type, By Application, By Route of Administration, By End User, By Treatment Model, By Molecule Source, By Distribution Channel, By Region |
| Top Key Players | Compass Pathways, Seelos Therapeutics, atai Life Sciences (AtaiBeckley), GH Research, Definium Therapeutics, Enveric Biosciences, Helius Pharma, Optimi Health, Johnson & Johnson, Numinus Wellness |
| Segment | Share 2025 (%) |
| Psilocybin | 34% |
| Ketamine & Esketamine | 29% |
| MDMA | 15% |
| LSD | 9% |
| DMT | 7% |
| Others | 6% |
The Psilocybin Segment Dominated the Market With 34% in 2025
The psilocybin segment led the psychedelic drugs market with 34% share in 2025 and is expected to witness the fastest growth with a CAGR during the forecast period, due to the expansion of clinical trials for depression and anxiety globally. Growth in the regulatory agencies supporting breakthrough therapy programs has also increased their use. Strong investor funding also accelerated their commercialization pipelines.
The ketamine & esketamine segment held the second-largest share of 29% of the market in 2025, due to rapid adoption in treatment-resistant depression, which supports revenue growth. Their established clinical use also improves physician confidence. Expanding psychiatric clinic networks also increases their accessibility.
The MDMA segment held 15% of the psychedelic drugs market share in 2025, due to PTSD-focused approvals and late-stage studies, which are stimulating their demand. Veteran mental health initiatives also support therapy adoption. Partnerships between biotech firms and clinics are also improving their scalability.
The LSD segment held 9% of the market share in 2025, due to microdosing research gaining popularity among mental health researchers. Academic institutions are increasing psychedelic neuroscience studies. Additionally, rising awareness is also improving their acceptance among psychiatrists.
| Segment | Share 2025 (%) |
| Depression | 38% |
| Post-Traumatic Stress Disorder (PTSD) | 21% |
| Anxiety Disorders | 14% |
| Substance Use Disorders | 13% |
| Bipolar Disorder | 4% |
| Chronic Pain & Neurological Disorders | 6% |
| Others | 4% |
The Depression Segment Dominated the Market With 38% in 2025
The depression segment accounted for the highest revenue share of 38% of the psychedelic drugs market in 2025, driven by growth in the prevalence of treatment-resistant depression, which boosts therapy demand. Strong clinical evidence supports psilocybin efficacy, which has increased its use. Healthcare systems prioritize innovative psychiatric care solutions, which encourages their adoption.
The post-traumatic stress disorder (PTSD) segment held the second-largest share of 21% of the market in 2025 and is expected to show the highest growth during the forecast period, due to rapidly expanding MDMA-assisted therapy programs across developed markets. Military and veteran health initiatives are also increasing their treatment adoption. Regulatory momentum is also accelerating their commercialization opportunities.
The anxiety disorders segment held 14% of the psychedelic drugs market share in 2025, due to growing mental health awareness, which increases patient diagnosis rates. Psychedelics show effectiveness in end-of-life anxiety management, which promotes their use. Telepsychiatry integration also improves patient access.
The substance use disorders segment held 13% of the market share in 2025, as addiction recovery programs increasingly incorporate psychedelic therapies. Opioid and alcohol dependency crises are also stimulating funding support. Rehabilitation centers seeking alternative relapse prevention solutions also increase their adoption.
| Segment | Share 2025 (%) |
| Oral | 46% |
| Nasal | 18% |
| Injectable | 17% |
| Sublingual/Buccal | 11% |
| Others | 8% |
The Oral Segment Dominated the Market With 46% in 2025
The oral segment held a major revenue share of 46% of the psychedelic drugs market in 2025, due to high use of capsule and tablet formats, which improved patient compliance. Oral administration also supported the outpatient psychiatric treatment models. Pharmaceutical companies also prioritized easy-to-scale dosage forms.
The nasal segment held the second-largest share of 18% of the market in 2025 and is expected to expand rapidly during the forecast period, as Esketamine nasal spray adoption is expanding rapidly in clinics. Their fast therapeutic onset also improves emergency psychiatric intervention. Regulatory approvals also strengthen physician confidence.
The injectable segment held 17% of the psychedelic drugs market share in 2025, due to a rise in hospital-based ketamine infusion programs globally. Their controlled dosing also improves safety management. Severe psychiatric cases also drive injectable therapy demand.
The sublingual/buccal segment held 11% of the market share in 2025, due to enhanced bioavailability, which improves therapeutic efficiency. Home-based supervised treatment models also encourage their adoption. Growing product innovations are also expanding the delivery options.
| Segment | Share 2025 (%) |
| Hospitals | 31% |
| Psychiatric Clinics | 24% |
| Rehabilitation Centers | 14% |
| Specialty Psychedelic Therapy Centers | 22% |
| Research Institutes | 9% |
The Hospitals Segment Dominated the Market With 31% in 2025
The hospitals segment contributed the biggest revenue share of 31% of the psychedelic drugs market in 2025, as hospitals manage complex psychiatric and infusion therapies effectively. Strong reimbursement systems also supported institutional treatment. Advanced monitoring infrastructure also improved safety outcomes.
The psychiatric clinics segment held the second-largest share of 24% of the market in 2025 due to the presence of specialized psychiatric services increasing psychedelic therapy adoption. A rise in outpatient mental health treatment also increased its demand. The presence of experienced psychiatrists also improves therapy acceptance.
The specialty psychedelic therapy centers segment held 22% of the psychedelic drugs market share in 2025, and is expected to gain the highest share during the forecast period due to the dedicated psychedelic wellness centers that are expanding in developed countries. Personalized therapy programs are also attracting premium patients. Venture capital funding also accelerates infrastructure development.
The rehabilitation centers segment held 14% of the market share in 2025, due to growing addiction treatment facilities integrating psychedelic-assisted therapies. Relapse prevention initiatives are also strengthening clinical adoption. Growing substance abuse rates also support market expansion.
| Segment | Share 2025 (%) |
| Psychedelic-Assisted Therapy | 58% |
| Standalone Pharmacotherapy | 29% |
| Integrated Digital Therapeutics & Monitoring | 13% |
The Psychedelic-Assisted Therapy Segment Dominated the Market With 58% in 2025
The psychedelic-assisted therapy segment held the largest revenue share of 58% of the psychedelic drugs market in 2025, as the combined psychotherapy and psychedelic treatment offered strong outcomes. Growth in the clinical guidelines supported assisted therapy models. Patient demand for holistic psychiatric care has also increased its use.
The standalone pharmacotherapy segment held the second-largest share of 29% of the market in 2025 and is expected to grow with the fastest CAGR during the forecast period, as pharmaceutical firms are developing simplified medication-only approaches. Broader physician adoption also improves prescription volume. Regulatory familiarity also supports commercialization pathways.
The integrated digital therapeutics & monitoring segment held 13% of the psychedelic drugs market share in 2025, due to growing remote patient monitoring, which improves treatment adherence. Increasing digital mental health platforms also expand therapy accessibility. AI-based behavioral tracking also enhances patient management.
North America dominated the psychedelic drugs market with 46% in 2025, due to favorable regulatory pathways that accelerate psychedelic drug approvals. Strong biotech investment also supported their commercialization activities. High mental health spending also enhanced treatment adoption, which contributed to the market growth.
U.S. Market Trends
FDA breakthrough therapy designations in the U.S. are stimulating innovations in psychedelic drugs. A large psychiatric patient population also increases its demand. Expanding psychedelic clinics improves accessibility of these drugs, where the rise in R&D activities is also driving their innovations.
Asia Pacific held 16% share of the psychedelic drugs market in 2025 and is expected to grow at the fastest CAGR during the forecast period, due to the rising mental health burden, which increases therapy demand. Governments expand psychiatric healthcare investments, promoting the development of psychedelic drugs. Clinical trials and biotech partnerships also accelerate the market growth.
India Market Trends
Rising awareness of mental wellness in India is driving interest in psychedelic drug research. Private healthcare investments are also supporting psychiatric innovation. Urban mental health initiatives also improve diagnosis rates, increasing their demand.
|
Ecosystem Segment
|
Key Participants | Role in Market |
| Technology Providers | Compass Pathways, GH Research, atai Life Sciences, Beckley Psytech | Develop novel psychedelic molecules and delivery technologies |
| Product Manufacturers | Johnson & Johnson, Optimi Health, Filament Health, Compass Pathways | Manufacture psychedelic therapeutics and APIs |
| Service Providers | Numinus Wellness, Field Trip Health, Delic Holdings | Psychedelic-assisted therapy delivery and patient services |
| Platform Providers | atai Life Sciences, Numinus Wellness | Integrated drug development and treatment platforms |
| CROs/CDMOs | Syneos Health, Thermo Fisher Scientific, Catalent, Labcorp Drug Development | Clinical trial execution and manufacturing support |
| Software Vendors | MindMed Digital Medicine, Clarion Clinics Digital Platforms | Patient monitoring, treatment analytics, digital therapeutics integration |
| Research Institutions | Johns Hopkins Center for Psychedelic & Consciousness Research, Imperial College London Centre for Psychedelic Research, MAPS | Clinical research and scientific validation |
| End-User Industries | Healthcare Providers, Mental Health Clinics, Hospitals, Rehabilitation Networks | Adoption and administration of psychedelic therapies |
R&D
Clinical Trials and Regulatory Approvals
Patient Support and Services
| Tier 1 | Tier 2 | Tier 3 | |
| Typical Market Influence | 62% | 28% | 10% |
| Tier 1 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| Johnson & Johnson | New Brunswick, New Jersey | USA | Only major pharmaceutical company with commercial psychedelic-related product generating substantial revenue | Spravato (Esketamine) |
| Compass Pathways | London, England | United Kingdom | Global leader in psilocybin drug development and late-stage clinical programs | COMP360 Psilocybin Therapy |
| atai Life Sciences | Berlin | Germany | Broad psychedelic pipeline and multiple portfolio companies | VLS-01, RL-007, Psychedelic Development Platform |
| Tier 2 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| Numinus Wellness | Vancouver, British Columbia | Canada | Major psychedelic therapy service provider with clinic network | MDMA-Assisted Therapy Programs |
| Beckley Psytech | Oxford, England | United Kingdom | Advanced psychedelic clinical pipeline and strategic partnerships | BPL-003 (Intranasal MeBufotenin) |
| Cybin Inc. | Toronto, Ontario | Canada | Strong proprietary psychedelic molecule portfolio | CYB003, CYB004 |
| Tier 3 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| Enveric Biosciences | Naples, Florida | USA | Developing next-generation neuroplastogenic compounds | EB-003 Program |
| Seelos Therapeutics | New York, New York | USA | Active neuropsychiatric pipeline involving psychedelic-related assets | SLS-002 |
| Reunion Neuroscience | Toronto, Ontario | Canada | Focused on serotonergic psychedelic therapeutics | RE104 |
Strengths
Weaknesses
Opportunities
Threats
By Drug Type
By Application
By Route of Administration
By End User
By Treatment Model
By Molecule Source
By Distribution Channel
By Region
Principal Consultant
Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and strategy.
Learn more about Shivani Zoting
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
+1 804-441-9344
